Antiplatelet Trialists´Collaboration. Collaborative overview of randomised trials of antipatelet theraphy. I: Prevention of death, myocardial infarction,and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106

Ambepitia G, Kopelman PG, Ingram D, Swash M, Mills PG, Timmis AD. Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function. J Am Coll Cardiol 1990; 15: 72-7

American Diabetes Asociation: Clinical Practice Recommendations 1999. Standars of Medical Care of Patients With Diabetes Mellitus. Diabetes Care 1999; 22 (suppl. 1): S 32- S 41

American Diabetes Association: Management of Dyslipemia in Adults with Diabetes.Diabetes Care 1999; 22 (Supl 1) S56-S59

Appel LJ, Moore TJ, Obarzanek E et al. For the DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on bood presure. N Engl J Med 1997; 336: 1117-24

Aspirin Therapy in diabetes. Diabetes Care 1999; 22 (suppl 1): S60-S61

Bakris JL, Weir MR, Sowers JR. Therapeutic challenges in the obese patient with hypertension. Am J Med 1996; 101: S33-S46

Bilo HJ, Gans RO. Hypertensive patients and diabetes: a high-risk population. J Cardiovas Pharmacol 1998; 32 (suppl. 2): S1-S8

Bjorck S, Mulec H, Jhonsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-43

Chadda K, Golstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503-10

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-20

Colhoun HM, Dong W, Barakat MT, Mather HM, Poulter NR. The scope for cardiovascular disease risk factor intervencion among people with diabetes mellitus in England: a population-based analysis from the Healh Surveys for England 1991- 94. Diabet Med 1999; 16: 35-40

Collado-Mesa F, Colhoun HM, Stevens LK et al. Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Diabet Med 1999; 16: 41-8

Consensus Statement. Treatment of Hypertension in Diabetes. Diabetes Care 1993; 16: 1394-1401

Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886-92

Davis BR, Langford HG, Blaufox MD, Curb JD, Polk BF, Shulman NB. The association of postural changes in systolic blood pressure and mortality in persons with hypertension: the Hypertension Detection and Follow-up Program experience. Circulation 1987; 75: 340-46

Diez J. La hipertrofia ventricular izquierda en la hipertensión arterial. Tecnigrafic SA. Madrid. 1991

Di Minno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986; 68: 886-91

Dodson PM, Horton RC. The hypertension of diabetes mellitus. Mechanisms and implications. J Hum Hypertens 1998; 1: 241-47

Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years´observations on male British doctors. BMJ 1994; 309: 901-911

Estacio RO,Jeffers JW, Hiatt WR, Biggersrtaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52

Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903

Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-18

Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Glifford N, Schier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent-diabetes and hypertension. N Engl J Med 1998; 338: 645-52

Factor SM, Okun EM, Minase T. Capillary microaneurysms in the human diabetic heart. N Engl J Med 1980; 302: 384-8

Fein FS, Scheuer J. Heart disease in diabetes. In : Rifkin H, Porte D eds. Diabetes mellitus: Theory and Practice. 4th ed. New York: Elsevier 1990; 812-23

Gil,V. Cumplimiento terapéutico. En:Tratado de Epidemiología clínica. Ed. Universidad de Alicante 1995. 537-549.

Goldberg RB; Mellies MJ; Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513-19

Grossman E, Hemesh J, Shamiss A, Thaler M, Carroll J, Rosenthal T. Left ventricular mass in diabetes-hypertension. Arch Intern Med 1992; 152: 1001-4

Grossman E, Messerli F. Diabetic and Hypertensive Heart Disease.Ann Intern Med 1996; 125: 304-10

Grossman E, Shemesh J, Shamiss A, Thaler M, Carroll J, Rosenthal T. Left ventricular mass in diabetes-hypertension. Arch Intern Med 1992; 152: 1001-4

Grundy S, Benjamin I, Burke G et al. Diabetes and Cardiovascular Disease. A Statement for Healthcare Professionals From the American Heart Association. Circulation 1999; 100: 1134-46

Grundy S, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessement Equation. A Statement for Healhcare Professionals From the American Heart Association and the American College of Cardiology. Circulation 1999; 100:1481-92

Grundy S, Ivor J, Gregory L et al. Diabetes and Cardiovascular Disease. A Statement for Healthcare Professionals From the American Heart Association. Circulation 1999; 100: 1134-46

Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. N Engl J Med 1998; 339: 229-34

Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6

Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62

Harris S, Meltzer S, Zinman B on behalf of the Steering Committee for the Revision of the Clinical Practice Guidelines for the Management of Diabetes in Canada. CMAJ 1998; 159: 973-8

Haynes RB. Introduction. En: Haynes RB, Taylor DW, Sackett DL (Eds) Compliance in health care. Baltimore. Johns Hopkins University Press, 1979:1-7.

Heise T, Magnusson K, Heinemann L, Sawicki PT. Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension 1998; 32: 243-8

Herlitz J, Malmberg K, Karlson BW, Ryden L, Hjarlmarson A. Mortality and morbidity during a five-years follow up of diabetics with myocardial infarction. Acta Med Scand 1988; 224: 31-8

Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309-17

Hypertension-Stroke Cooperative Study Group. Effects of Antihypertensive Treatment on Stroke recurrence. JAMA 1974; 229: 409-18

Jacob S, Rett K, Wicklmaryr M, Agrawal B, Augustin HJ and Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertension 1996; 14: 489-494

Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-183

Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study.JAMA 1979; 241: 1225-9

Lewis EJ, Hubsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. The - Collaborative Study Group. N Engl J Med 1993; 329: 1456-62

Lithell H et al. Effect of hypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991; 14: 203-209

McLeod MJ, McLay J. Drug Treatment of Hypertension Complicating Diabetes Mellitus. Drugs 1998;56: 189-201

McPhillips JB,Barret-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol 1990:131: 443-53

Melchior T, Kober L,Madsen CR et al. Accelerating impact of diabetes mellitus on mortality in the years following an acute myocardial infarction.TRACE Study Group. Trandolapril Cardiac Evaluation.European Haeart Journal 1999; 20: 973-8

Miettinen, H, Letho S, Salomaa V et al. Impact of Diabetes on Mortality After the First Myocardial Infarction. Diabetes Care 1998; 21: 69- 75

Moye LA, Pfeffer MA, Wun CC et al.Uniformity of captopril benefit in the SAVE study: subgroup analysis. Europ Heart J 1994; 15: S2-S8

Nagano N, Nagano M, Yo Y et al. Role of glucose intolerance in cardiac diastolic function in essential hypertension. Hypertension 1994; 23: 1002-5

Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46: 1182-88

Paffenbarger RS, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328: 538-45

Pahor M, Psaty BM, Furberg CD. New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. J Cardiovasc Pharmacol 1998; 32(Supp 2): S18-S23

Parving H-H. Diabetic Hypertensive Patients. Is this a group in need of particular care and attention?.Diabetes Care 1999; 22 (suppl. 2): B 76- B80

Pell S, D´Alonso CA. Some aspects of hypertension in diabetes mellitus. JAMA 1967; 202: 10-6

Prados JA. Importancia de la relación médico paciente y la entrevista clínica en el cumplimiento terapéutico. Información Terapéutica del Servicio Nacional de Salud. 1992; 16: 209-216.

Prevention of coronary heart disease in clinical practice. Second Joint Task Force of European and other Societies. European Heart Journal 1998; 19:1434-1503

Pyorala K, Pedersen TR, Kjekshus J, Faegeman O, Olsson AG, Thorgeirsson G. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol-lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89

Ramsay L, Haq I, Jackson P, YeoW, Pickin D, Payne J. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an Update Sheffield table. Lancet 1996; 348: 387-88

Ruilope LM, Garcia-Robles R. How far should blood pressure be reduced in diabetic hypertensive patients. Journal of Hypertension 1997; 15 (supp. 2): S63-S65

Sahai A, Ganguly PK. Congestive heart failure in diabetes with hypertension may be due to uncoupling of the atrial natriuretic peptide receptor-effector system in the kidney basolateral membrane. Am Heart J 1991; 122: 164-70

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol-lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89

Schrier RW, Estacio RO, Jeffers B. Appropiate Blood Presure Control in NIDDM (ABCD) Trial. Diabetologia 1996; 39: 1646-54

SHEP Cooperative Research Group. Prevention of stroke by hypertensive drug treatmenta in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991; 265: 3255-64

Shepherd J, Cobbe SM, Ford I et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7

StamlerJ, Vaccaro O, Neaton JD, Wentworth for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors and 12-year cardiovascular mortality for men screemed in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444

Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 1986; 6: 123-30

Sonnenblick FH. Diabetes insulinodependiente y corazón hipertenso. Mighlights of the 12th Annual Meeting of the American Society of Hypertension. Kaplen N ed (ed esp.) Barcelona (España) Medical Trades (SL). 1998; 78-80

StamlerJ, Vaccaro O, Neaton JD, Wentworth for the Multiple Risk Factor 12-year cardiovascular mortality for men screemed in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444

Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomised Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603

The Diabetes Intervention Trial Research Group. Diabetes, other risk factors and Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the developement and progresion of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-88

The Medical Research Council´s General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men al increased risk. Lancet 1998; 351: 233-41

The SOLVD investigators. Effect of enalapril on mortality and developement of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1995; 322: 80-85

Thygesn K, Strate M, Hansen L, Harwald B. Survival of diabetic hypertensive patients. Hypertension 1985; 7 (suppl.II): 14-17

Tonkin A, Simes J for Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med 1998; 339: 1349-57

Tudor Hart. Cumplimiento terapéutico. Atención Primaria 1994; 1: 109-115).

Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677-84

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 837-53

UK Prospective Diabetes Study Group. (UKPDS 6). Diabetes Research 1990; 13: 1-11

UK Prospective Diabetes Study (UKPDS) Group. Tight blood presure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. BMJ 1998; 317: 703- 13

UK Prospective Diabetes Study (UKPDS) Group. Tight blood presure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. BMJ 1998; 317: 703- 13

UK Prospective Study. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20

Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996; 27: 481-490

Wilson PW, D´Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories.Circulation 1998; 97: 1837-47

World Health Organization – International Society of Hypertension Guidelines for the management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17:151- 83